Salivary Gland Cancer: A Rare Diagnosis With Varied Outcomes
When 62-year-old Margaret noticed a slowly growing, painless lump in front of her left ear that had been present for six months, she assumed it was a benign cyst. But fine-needle aspiration biopsy revealed adenoid cystic carcinoma of the parotid gland—one of over 20 distinct types of salivary gland cancer. “My surgeon explained that ‘salivary gland cancer’ isn’t really one disease,” Margaret recalled. “It’s dozens of different cancers, each with different behavior. Mine grows slowly but spreads along nerves and can recur decades later.” The disease’s five-year survival rate is 76%. The survival rate changes for different subtypes of salivary gland cancer, though. Salivary gland tumors form when a cell in a salivary gland mutates and starts rapidly growing and dividing. Most salivary gland tumors are benign, meaning they are not cancer and do not spread to other parts of the body. Some are malignant, or cancer. These tumors can spread beyond their original location to nearby tissue, lymph nodes and distant parts of the body MD Anderson Cancer Center. Understanding salivary gland cancer requires recognizing that location, histologic type, tumor grade, and stage create dramatically different prognoses—from near-certain cure to aggressive disease requiring multimodal treatment.
The Anatomy: Three Major Glands, Hundreds of Minor Ones
Each person has hundreds of salivary glands. There are two types: the major salivary glands and the minor salivary glands. Most saliva is produced from the three pairs of major salivary glands. Most salivary gland tumors occur in the major glands. The parotid glands are the largest pair of salivary glands, located just in front of each ear. Most salivary gland tumors start here. The submandibular glands are smaller than the parotid glands and sit below the jaw. Sublingual glands are the smallest of the major salivary glands and sit under the floor of the mouth and below either side of the tongue. There are also several hundred minor salivary glands that are too small to see without special lab equipment. These glands are under the lining of the lips and tongue; in the roof of the mouth; and inside the cheeks, nose, sinuses, and larynx MD Anderson Cancer CenterAmerican Cancer Society. The Parotid Paradox: about 70% of all salivary gland tumors arise in parotid glands, but only 25% of parotid tumors are malignant. A good rule of thumb to remember is the rule of 80s; that 80% of all salivary tumors are in the parotid, 80% of parotid tumors are benign, and 80% of the benign tumors that arise in the parotid are pleomorphic adenomas. The most common malignant tumor is mucoepidermoid carcinoma, followed by acinic cell carcinoma and adenoid cystic carcinoma NCBI. Submandibular Glands: about 10% of salivary tumors, but 43% are malignant—higher malignancy rate than parotid. Minor Salivary Glands: rare tumor site (less than 4% of cases), but when tumors occur here, 82% are malignant. Most commonly affect hard palate.
The Many Faces: Over 20 Histologic Subtypes
Salivary gland cancer encompasses extraordinary histologic diversity—over 20 distinct malignant types, each with unique biology and prognosis. Mucoepidermoid carcinomas are the most common type of salivary gland cancer. About 1 in 3 salivary gland cancers are mucoepidermoid carcinomas. Most start in the parotid glands. They develop less often in the submandibular glands or in minor salivary glands inside the mouth. While cancer of the salivary glands is rare in children, it is the most common type of pediatric salivary gland cancer American Cancer Society. Mucoepidermoid carcinoma divides into low, intermediate, and high grade. Low-grade tumors behave indolently; high-grade tumors behave aggressively like squamous cell carcinoma. Adenoid cystic carcinoma is the second most common type of salivary gland cancer. It is usually slow-growing and can start in the major or minor salivary glands. It can be hard to get rid of completely because it tends to spread along the nerves and can spread to distant areas like the lungs as well. These tumors can come back after treatment, sometimes many years later. The outlook tends to be better if the tumor is smaller. Adenoid cystic carcinoma, the most common tumor of the minor salivary glands and second most common of the major salivary glands. This tumor tends to grow along nerves, particularly the facial and trigeminal nerves American Cancer SocietyMD Anderson Cancer Center. This perineural invasion pattern explains why adenoid cystic carcinoma causes pain, numbness, or facial weakness—and why recurrences happen decades post-treatment when tumor cells dormant in nerve sheaths reactivate. Acinic cell carcinoma: mostly parotid origin, generally low-grade with excellent prognosis but recurrence tendency. Salivary duct carcinoma: aggressive, resembles breast ductal carcinoma, often expresses androgen receptors or HER2—opening targeted therapy options. Carcinoma ex pleomorphic adenoma: malignancy arising in long-standing benign pleomorphic adenoma—emphasizes importance of removing even benign salivary tumors. Polymorphous adenocarcinoma: usually minor salivary glands, favorable prognosis after surgery. Secretory carcinoma: recently described entity with ETV6-NTRK3 gene fusion, targetable with TRK inhibitors.
Symptoms: The Painless Lump and Ominous Signs
Most patients with benign tumors of the major or minor salivary glands present with painless swelling of the parotid, submandibular, or sublingual glands. Neurological signs, such as numbness or weakness caused by nerve involvement, typically indicate a malignancy. Facial nerve weakness associated with a parotid or submandibular tumor is an ominous sign. Persistent facial pain is highly suggestive of malignancy. Approximately 10% to 15% of malignant parotid neoplasms present with pain. However, most parotid tumors, both benign and malignant, present as an asymptomatic mass in the gland NCINCBI. The challenge: most salivary gland cancers present identically to benign tumors—slow-growing, painless lumps discovered incidentally or during dental exams. Concerning features suggesting malignancy: rapid growth over weeks to months; facial weakness, numbness, or asymmetry; facial pain radiating to ear; difficulty opening mouth (trismus); skin fixation or ulceration; hard, fixed mass; enlarged neck lymph nodes; and difficulty swallowing. The facial nerve runs directly through parotid gland. Facial paralysis with parotid mass indicates nerve invasion—virtually diagnostic of malignancy. Most benign tumors push nerve aside; malignant tumors invade through nerve.
Diagnosis: Fine-Needle Aspiration and Imaging
Fine-needle aspiration biopsy (FNA) is the primary diagnostic tool for salivary gland lesions, but the role of FNA in the diagnosis of benign and malignant salivary gland disease still carries some controversy. It is a relatively painless procedure, has few complications (seeding of the tumor does not seem to occur), and may prevent an ill-advised and often ill-fated incisional or excisional biopsy of a parotid mass NCBI. FNA provides cytology—cell appearance—but not architecture, making definitive diagnosis challenging for some subtypes. CT scans show tumor size, bone invasion, and lymph node involvement. MRI superior for soft tissue detail, nerve pathway involvement, and perineural spread. PET scans assess distant metastases. Definitive diagnosis usually requires surgical excision with pathologic examination. Never perform incisional biopsy of parotid masses—risk tumor spillage and facial nerve injury. The diagnostic sequence: clinical examination identifying mass → FNA suggesting malignancy → imaging defining extent → surgical excision providing definitive diagnosis and treatment.
Staging and Grading: Size, Spread, and Biology
The following staging system applies only to the major salivary glands, which include the parotid, submandibular, and sublingual glands. Stage I describes a very early stage of cancer. The tumor is not more than 2 centimeters, and the cancer has not reached the lymph nodes. Stage II describes a tumor that is larger than 2 centimeters but not more than 4 centimeters. Stage II cancer has not reached the lymph nodes. Stage III salivary gland cancer describes cancer that either is larger than 4 centimeters or has spread to a lymph node in the neck. Stage IV is the most advanced stage of salivary gland cancer Memorial Sloan Kettering Cancer Center. Grading assesses tumor aggressiveness under microscope. Most salivary gland cancers are also characterized according to their grade. The grade of a tumor tells how fast the cancer cells are growing, based on how the cells look under a microscope. Salivary gland cancers are either low grade or high grade. Low-grade cancers grow more slowly than high-grade cancers. A higher-grade cancer may require immediate or more-aggressive treatment Memorial Sloan Kettering Cancer Center. Low-grade mucoepidermoid carcinoma: excellent prognosis, rarely metastasizes, curable with surgery alone. High-grade mucoepidermoid carcinoma: aggressive behavior similar to squamous cell carcinoma, frequent lymph node metastases, requires multimodal treatment.
Treatment: Surgery First, Radiation Often
Early-stage, low-grade, malignant salivary gland tumors are usually curable by adequate surgical resection alone. The prognosis is more favorable when the tumor is in a major salivary gland. The parotid gland is most favorable followed by the submandibular gland NCI. Surgical principles: complete tumor excision with negative margins, facial nerve preservation when oncologically safe, neck dissection for high-grade tumors or clinical lymph node involvement. For parotid cancer, superficial parotidectomy removes superficial lobe (containing most tumors) while preserving facial nerve. Total parotidectomy removes entire gland when tumor involves deep lobe. Radical parotidectomy sacrifices facial nerve when directly invaded—followed by nerve graft reconstruction. The facial nerve dilemma: preservation maintains normal facial movement; resection improves cancer control. In early-stage low- and intermediate-grade parotid cancers, complete surgical resection with close margins has been shown to result in excellent disease control, supporting the concept of facial nerve preservation in these patients. For advanced and high-grade tumors, it is less clear American Society of Clinical Oncology. Postoperative radiation therapy indications: Postoperative radiation therapy should be offered to all patients with resected adenoid cystic carcinoma. Postoperative RT should be offered to patients with tumors with the following features: high-grade tumors, positive margins; perineural invasion; lymph node metastases; lymphatic or vascular invasion; and T3-T4 tumors. The addition of adjuvant radiation therapy was associated with improved 5-year survival rates (82.4% vs. 72.5%) compared to surgery alone American Society of Clinical OncologyIn Vivo. Adenoid cystic carcinoma receives radiation regardless of stage due to perineural spread tendency—radiation fields include entire nerve pathway to skull base.
Survival: The Histology-Location-Grade Equation
Location of the tumor: Tumors in the major salivary glands (parotid, submandibular, and sublingual glands) tend to have a better outlook than tumors in the minor salivary glands. Size of the tumor: Smaller tumors respond better to treatment than larger tumors. Type of salivary gland tumor: Certain types of salivary gland tumors may respond better to treatment than others. For example, polymorphous adenocarcinomas tend to respond well to treatment. With salivary gland cancer, survival rates depend on the type of cancer. For example, the survival rate for mucoepidermoid carcinoma ranges from 75% to 90% at five years. The location of the tumor matters, too. If it’s only in your salivary gland, the survival rate is 94%. The survival rate is lower if the cancer’s spread American Cancer SocietyCleveland Clinic. Breaking down by stage and location: Localized disease (confined to salivary gland): 94% five-year survival—surgery alone often curative. Regional disease (lymph node spread, large size, extraparenchymal extension): 69% five-year survival—requires surgery plus radiation, often chemotherapy. Distant disease (lung, bone, liver metastases): 39% five-year survival—palliative intent treatment. Submandibular gland adenoid cystic carcinomas had the worst prognosis (adjusted disease-specific survival hazard ratio = 1.48 compared to parotid), and this difference was more pronounced among patients with advanced-stage tumors (adjusted DSS HR = 1.93). Adjuvant radiotherapy was associated with increased overall survival only among stage III submandibular ACC patients (HR = 0.64) and had no benefit in any other group PubMed Central. Why submandibular worse? Closer proximity to vital structures, later diagnosis, different tumor biology.
Special Considerations: The Late Recurrence Problem
Adenoid cystic carcinoma presents unique challenge: slow growth but relentless progression. For those who achieve remission, ongoing monitoring remains vital due to the possibility of late recurrence, which can occur years after initial treatment, particularly with certain aggressive tumor types like adenoid cystic carcinoma. Some types, like mucoepidermoid carcinoma and acinic cell carcinoma, generally have a more favorable outlook, especially when diagnosed early. More aggressive types, such as adenoid cystic carcinoma or carcinoma ex pleomorphic adenoma, may have a higher risk of recurrence or metastasis, leading to a less favorable prognosis Massive Bio. Patients cured of adenoid cystic carcinoma require lifelong surveillance—recurrences documented 20-30 years post-treatment. The perineural spread creates microscopic disease along nerve sheaths impossible to detect or completely remove surgically. Tumor cells remain dormant for years, then reactivate. Lung metastases common with adenoid cystic carcinoma—can remain asymptomatic for years, growing slowly. Some patients live decades with stable lung metastases. This challenges traditional cancer cure definitions.
Risk Factors: Mostly Unknown
Risk factors for salivary gland cancer include: Age: Most cases of salivary gland cancer are diagnosed in people aged 55 or older. Prior radiation to the head and neck: Patients who received radiation treatment to the head and neck for another cancer have a higher risk of developing salivary gland cancer. Fortunately, the benefits of radiation therapy far outweigh this risk. Radiation exposure has been linked to parotid gland carcinomas 15 years after the event. Cigarette smoking and alcohol is associated with head and neck squamous cell carcinoma, skin malignancies in the head and neck have been known to metastases to the parotid glands MD Anderson Cancer CenterNCBI. Unlike most head-neck cancers, salivary gland cancers show no strong tobacco-alcohol association. Previous radiation exposure (childhood cancer treatment, atomic bomb survivors) increases risk decades later. Occupational exposures to certain industrial compounds, metals, and rubber manufacturing have been suggested but evidence remains weak. No clear hereditary syndromes identified. Most cases arise sporadically without identifiable cause. The parotid gland also serves as metastatic site for skin cancers—melanoma and squamous cell carcinoma from scalp, temple, ear—spreading via lymphatics to parotid nodes.
Frequently Asked Questions
Q1: I have a lump in front of my ear. How worried should I be about cancer?
Most parotid lumps are benign. Remember the rule of 80s: 80% of parotid tumors are benign. However, you should see an ENT surgeon or head-neck specialist promptly for evaluation. Key concern features: rapid growth, facial weakness/numbness, pain, hard/fixed mass, skin changes, difficulty opening mouth. Even if examination suggests benign tumor, most surgeons recommend surgical removal because: (1) definitive diagnosis requires pathologic examination—FNA provides clues but not certainty; (2) benign pleomorphic adenomas can transform into cancer if left in place years; (3) continued growth eventually causes facial nerve compression even if benign. Early evaluation and appropriate management prevent complications.
Q2: If I need parotid surgery, will I have permanent facial paralysis?
For most parotid cancers, surgeons preserve facial nerve, maintaining normal facial function. Temporary weakness occurs commonly after surgery due to nerve manipulation—this typically resolves over weeks to months as nerve inflammation subsides. Permanent paralysis occurs when: (1) cancer directly invades nerve requiring sacrifice for complete tumor removal; (2) nerve injured during surgery (rare in experienced hands). Even when nerve must be sacrificed, immediate nerve graft reconstruction often achieves reasonable facial function—not perfect but functional. Physical therapy and sometimes additional procedures (gold weight in eyelid, facial reanimation surgery) optimize outcomes. Discuss your specific case with surgeon—nerve preservation rates exceed 90% for most parotid cancers.
Q3: I was diagnosed with adenoid cystic carcinoma. My surgeon says I’m cured, but my radiation oncologist says it can recur decades later. Which is right?
Both are correct—adenoid cystic carcinoma presents unique paradox. Five-year survival rates appear excellent, suggesting cure. But late recurrences—10, 20, even 30 years post-treatment—occur with adenoid cystic carcinoma more than any other cancer. The perineural spread pattern creates microscopic disease along nerve pathways impossible to completely eliminate. Tumor cells remain dormant for years, then reactivate unpredictably. This necessitates lifelong surveillance with annual chest imaging detecting lung metastases early. Many patients live normal lifespans despite “incurable” lung metastases that grow so slowly they never cause symptoms. View adenoid cystic carcinoma as manageable chronic disease rather than cured cancer.
Q4: Are there any targeted therapies for salivary gland cancer?
Emerging options exist, particularly for specific subtypes. Salivary duct carcinoma frequently expresses androgen receptors (like prostate cancer) or HER2 (like breast cancer)—both targetable. Clinical trials evaluating androgen deprivation therapy (enzalutamide, abiraterone) and HER2-targeted therapy (trastuzumab, pertuzumab) show promising results in advanced salivary duct carcinoma. Secretory carcinoma harbors ETV6-NTRK3 fusion—responds dramatically to TRK inhibitors (larotrectinib, entrectinib), though this subtype is rare. Clinical trials testing immunotherapy (checkpoint inhibitors), mTOR inhibitors, and other targeted agents are ongoing. For most patients, surgery and radiation remain standard treatment. Targeted therapy primarily applies to advanced/metastatic disease where surgery-radiation exhausted. Molecular profiling of tumor increasingly recommended identifying targetable alterations.
Q5: Can I prevent salivary gland cancer?
Unlike tobacco-related head-neck cancers, no clear prevention strategies exist for most salivary gland cancers. The lack of strong lifestyle risk factors means standard cancer prevention advice (avoid tobacco, limit alcohol, healthy diet, exercise) doesn’t specifically reduce salivary gland cancer risk. The one exception: children receiving radiation therapy for other cancers (leukemia, brain tumors) face increased salivary gland cancer risk decades later—modern radiation techniques minimize salivary gland exposure. Early detection through awareness of warning signs (new mass, facial weakness, pain) and prompt evaluation of persistent lumps offers best approach. Regular dental exams may detect parotid masses early.
Disclaimer
This article adapts publicly available information from reputable cancer research organizations and medical databases. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider. Decisions about salivary gland cancer screening, diagnosis, and treatment should be made in consultation with qualified ENT surgeons, head and neck oncologists, radiation oncologists, and pathologists who can evaluate your individual tumor characteristics, stage, histology, and health status. If you have a mass in your salivary glands or symptoms concerning for salivary gland cancer, please consult with your healthcare team promptly.
References
- American Cancer Society. Survival Rates for Salivary Gland Cancer. https://www.cancer.org/cancer/types/salivary-gland-cancer/detection-diagnosis-staging/survival-rates.html
- MD Anderson Cancer Center. Salivary Gland Cancer. https://www.mdanderson.org/cancer-types/salivary-gland-cancer.html
- Memorial Sloan Kettering Cancer Center. Salivary Gland Cancer Stages. https://www.mskcc.org/cancer-care/types/salivary-gland/salivary-gland-cancer-diagnosis/stages-salivary-gland
- NCI. Salivary Gland Cancer Treatment (PDQ®). https://www.cancer.gov/types/head-and-neck/hp/adult/salivary-gland-treatment-pdq
- StatPearls. Parotid Cancer. https://www.ncbi.nlm.nih.gov/books/NBK538340/
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
